{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:08:55Z","timestamp":1761894535738},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2007,6,6]],"date-time":"2007-06-06T00:00:00Z","timestamp":1181088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1007\/s00115-007-2297-x","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T11:45:02Z","timestamp":1180957502000},"page":"1389-1398","source":"Crossref","is-referenced-by-count":5,"title":["Stellenwert der Uveitis im Rahmen demyelinisierender Erkrankungen des Zentralnervensystems"],"prefix":"10.1007","volume":"78","author":[{"given":"A.-M.","family":"Beyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Rosche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.P.","family":"Wandinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,6,6]]},"reference":[{"key":"2297_CR1","unstructured":"Schmidt RM, Hoffmann FA (Hrsg) (2006) Multiple Sklerose. Urban & Fischer, M\u00fcnchen"},{"key":"2297_CR2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/brain\/awg045","volume":"126","author":"Kidd","year":"2003","unstructured":"Kidd D, Burton B, Plant GT, Graham EM (2003) Chronic relapsing inflammatory optic neuropathy (CRION). Brain 126: 276\u2013284","journal-title":"Brain"},{"key":"2297_CR3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s004150050015","volume":"247","author":"Horvath","year":"2000","unstructured":"Horvath R, Abicht A, Shoubridge EA et al. (2000) Leber\u2019s hereditary optic neuropathy presenting as multiple sclerosis-like disease of the CNS. J Neurol 247: 65\u201367","journal-title":"J Neurol"},{"key":"2297_CR4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0002-9394(14)74235-7","volume":"103","author":"Bloch-Michel","year":"1987","unstructured":"Bloch-Michel E, Nussenblatt RB (1987) International uveitis study group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 103: 234\u2013235","journal-title":"Am J Ophthalmol"},{"key":"2297_CR5","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.semarthrit.2004.05.002","volume":"34","author":"Pras","year":"2004","unstructured":"Pras E, Neumann R, Zandman-Goddard G et al. (2004) Intraocular inflammation in autoimmune diseases. Semin Arthritis Rheum 34: 602\u2013609","journal-title":"Semin Arthritis Rheum"},{"key":"2297_CR6","doi-asserted-by":"crossref","unstructured":"Maca SM, Scharitzer M, Barisani-Asenbauer T (2006) Uveitis and neurologic diseases: an often overlooked relationship. Wien Klin Wochenschr 118\/9\u201310: 273\u2013279","DOI":"10.1007\/s00508-006-0601-6"},{"key":"2297_CR7","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1136\/bjo.2003.040519","volume":"88","author":"Smith","year":"2004","unstructured":"Smith JR, Rosenbaum JT (2004) Neurological concomitants of uveitis. Br J Ophthalmol 88: 1498\u20131499","journal-title":"Br J Ophthalmol"},{"key":"2297_CR8","first-page":"176","volume":"19","author":"Rucker","year":"1944","unstructured":"Rucker CW (1944) Sheathing of the retinal veins in multiple sclerosis. Mayo Clin Proc 19: 176\u2013178","journal-title":"Mayo Clin Proc"},{"key":"2297_CR9","unstructured":"Newman NJ (1998) Multiple Sclerosis. In: Miller NR, Newman NJ (eds) Walsh and Hoyt\u201as clinical neuroophthalmology. 5th edn. Williams & Wilkins, Baltimore, pp\u00a05539\u20135676"},{"key":"2297_CR10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/WNL.52.1.179","volume":"52","author":"Biousse","year":"1999","unstructured":"Biousse V, Trichet C, Bloch-Michel E, Roullet E (1999) Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 52: 179\u2013181","journal-title":"Neurology"},{"key":"2297_CR11","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0161-6420(93)31567-8","volume":"100","author":"Malinowski","year":"1993","unstructured":"Malinowski SM, Pulido JS, Folk JC (1993) Long term visual outcome and complications assiociated with pars planitis. Ophthalmology 100: 818\u2013825","journal-title":"Ophthalmology"},{"key":"2297_CR12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1442-9071.2000.00282.x","volume":"28","author":"Wakefield","year":"2000","unstructured":"Wakefield D, Jennings SA, McCluskey PJ (2000) Intravenous pulse methylprednisolone in the treatment of uveitis associated with multiple sclerosis. Clin Exp Ophthalmol 28: 103\u2013106","journal-title":"Clin Exp Ophthalmol"},{"key":"2297_CR13","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bjo.2004.061119","volume":"89","author":"Becker","year":"2005","unstructured":"Becker MD, Heiligenhaus A, Hudde T et al. (2005) Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 89: 1254\u20131257","journal-title":"Br J Ophthalmol"},{"key":"2297_CR14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00002018-200326010-00003","volume":"26","author":"Mikuls","year":"2003","unstructured":"Mikuls TR, Moreland LW (2003) Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Saf 26: 23\u201332","journal-title":"Drug Saf"},{"key":"2297_CR15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","volume":"53","author":"The","year":"1999","unstructured":"The Lenercept Study Group, The University of British Columbia MS\/MRI Analysis Group (1999) TNF neutralization in MS: Results of a randomized, placebo-controlled muticenter study. Neurology 53: 457\u2013465","journal-title":"Neurology"},{"key":"2297_CR16","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","volume":"47","author":"Oosten","year":"1996","unstructured":"Oosten BW van, Barkhof F, Truyen L et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531\u20131534","journal-title":"Neurology"},{"key":"2297_CR17","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1167\/iovs.05-1242","volume":"47","author":"Adamus","year":"2006","unstructured":"Adamus G, Burrows GG, Vandenbark AA, Offner H (2006) Treatment of autoimmune anterior uveitis with recombinant TCR ligands. Invest Ophthalmol Vis Sci 47: 2555\u20132561","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2297_CR18","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1212\/WNL.50.3.708","volume":"50","author":"S\u00f6derstr\u00f6m","year":"1998","unstructured":"S\u00f6derstr\u00f6m M, Ya-Ping J, Hillert J, Link H (1998) Optic neuritis: prognosis for multiple sclerosis from MRI, CSF and HLA-findings. Neurology 50: 708\u2013714","journal-title":"Neurology"},{"key":"2297_CR19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1034\/j.1600-0420.2001.790302.x","volume":"79","author":"S\u00f6derstr\u00f6m","year":"2001","unstructured":"S\u00f6derstr\u00f6m M (2001) Optic neuritis and multiple sclerosis. Acta Ophthalmol Scand 79: 223\u2013227","journal-title":"Acta Ophthalmol Scand"},{"key":"2297_CR20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1212\/WNL.38.2.185","volume":"38","author":"Rizzo","year":"1988","unstructured":"Rizzo JF 3rd, Lessell S (1988) Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long term prospective study. Neurology 38: 185\u2013190","journal-title":"Neurology"},{"key":"2297_CR21","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/archopht.121.7.944","volume":"121","author":"Optic","year":"2003","unstructured":"Optic Neuritis Study Group (2003) High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis \u2013 experience of the optic neuritis treatment trial. Arch Ophthalmol 121: 944\u2013949","journal-title":"Arch Ophthalmol"},{"key":"2297_CR22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1212\/WNL.45.2.244","volume":"45","author":"Rodriguez","year":"1995","unstructured":"Rodriguez M, Siva A, Cross SA et al. (1995) Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 45: 244\u2013250","journal-title":"Neurology"},{"key":"2297_CR23","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ana.410270406","volume":"27","author":"Sandberg-Wollheim","year":"1990","unstructured":"Sandberg-Wollheim M, Bynke H, Cronqvist S et al. (1990) A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol 27: 386\u2013393","journal-title":"Ann Neurol"},{"key":"2297_CR24","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","volume":"343","author":"Jacobs","year":"2000","unstructured":"Jacobs LD, Beck RW, Simon JH et al. (2000) Intramuscular Interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343: 898\u2013904","journal-title":"N Engl J Med"},{"key":"2297_CR25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0002-9394(01)01209-0","volume":"132","author":"CHAMPS","year":"2001","unstructured":"CHAMPS Study Group (2001) Interferon \u03b2-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 132: 463\u2013471","journal-title":"Am J Ophthalmol"},{"key":"2297_CR26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/brain\/121.3.495","volume":"121","author":"O","year":"1998","unstructured":"O\u2018Riordan JI, Thompson AJ, Kingsley DP (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 121: 495\u2013503","journal-title":"Brain"},{"key":"2297_CR27","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/WNL.49.5.1404","volume":"49","author":"Optic","year":"1997","unstructured":"Optic Neuritis Study Group (1997) The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 49: 1404\u20131413","journal-title":"Neurology"},{"key":"2297_CR28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMoa011341","volume":"346","author":"Brex","year":"2002","unstructured":"Brex PA, Ciccarelli O, O\u2018Riordan JI et al. (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346: 158\u2013164","journal-title":"N Engl J Med"},{"key":"2297_CR29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/BF02033357","volume":"241","author":"S\u00f6derstr\u00f6m","year":"1994","unstructured":"S\u00f6derstr\u00f6m M, Lindqvist M, Hillert J et al. (1994) Optic neuritis: findings on MRI, CSF, examination and HLA class II typing in 60 patients and results of a short-term follow-up. J Neurol 241: 391\u2013397","journal-title":"J Neurol"},{"key":"2297_CR30","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s004150050453","volume":"246","author":"Ghezzi","year":"1999","unstructured":"Ghezzi A, Martinelli V, Torri V (1999) Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome and the prognostic role of paraclinical tests. J Neurol 246: 770\u2013775","journal-title":"J Neurol"},{"key":"2297_CR31","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/01.wnl.0000237354.10144.ec","volume":"67","author":"Tintore","year":"2006","unstructured":"Tintore M, Rovira A, Rio J et al. (2006) Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67: 968\u2013972","journal-title":"Neurology"},{"key":"2297_CR32","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.ajo.2005.01.031","volume":"139","author":"Arnold","year":"2005","unstructured":"Arnold AC (2005) Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol 139: 1101\u20131108","journal-title":"Am J Ophthalmol"},{"key":"2297_CR33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM et al. (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326: 581\u2013588","journal-title":"N Engl J Med"},{"key":"2297_CR34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0002-9394(03)00862-6","volume":"137","author":"Optic","year":"2004","unstructured":"Optic Neuritis Study Group (2004) Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 137: 77\u201383","journal-title":"Am J Ophthalmol"},{"key":"2297_CR35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1191\/1352458504ms1087oa","volume":"10","author":"Edwards","year":"2004","unstructured":"Edwards LJ, Constantinescu CS (2004) A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler 10: 575\u2013581","journal-title":"Mult Scler"},{"key":"2297_CR36","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0161-6420(99)90122-7","volume":"106","author":"Raja","year":"1999","unstructured":"Raja SC, Jabs DA, Dunn JP et al. (1999) Clinical features and class II HLA associations. Ophthalmology 106: 594\u2013599","journal-title":"Ophthalmology"},{"key":"2297_CR37","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/(SICI)1097-4547(19960615)44:6<513::AID-JNR1>3.0.CO;2-E","volume":"44","author":"Adamus","year":"1996","unstructured":"Adamus G, Amundson D, Vainiene M et al. (1996) Myelin basic protein specific T-helper cells induce experimental anterior uveitis. J Neurosci Res 44: 513\u2013518","journal-title":"J Neurosci Res"},{"key":"2297_CR38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000076892","volume":"36","author":"Gorczyca","year":"2004","unstructured":"Gorczyca WA, Ejma M, Witkowska D et al. (2004) Retinal antigens are recognized by antibodies present in sera of patients with multiple sclerosis. Ophthalmic Res 36: 120\u2013123","journal-title":"Ophthalmic Res"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-007-2297-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-007-2297-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-007-2297-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:08:29Z","timestamp":1558588109000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-007-2297-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,6]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["2297"],"URL":"https:\/\/doi.org\/10.1007\/s00115-007-2297-x","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,6]]}}}